Author(s):
Rajesh A. Maheshwari, Aditya Agrawal, Meet Patel, Mansi Maheshwari, Vipul Patil, Rajesh Hadia, Hemraj Singh Rajput
Email(s):
hemrajs119@gmail.com
DOI:
10.52711/0974-360X.2025.00826 
Address:
Rajesh A. Maheshwari1, Aditya Agrawal2, Meet Patel1, Mansi Maheshwari1, Vipul Patil1, Rajesh Hadia1, Hemraj Singh Rajput1*
1Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara - 391760, Gujarat, India.
2Department of Orthopaedic, Shri B. K. Shah Medical Institute and Research Centre, Piparia, Vadodara - 391760, Gujarat, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 12,
Year - 2025
ABSTRACT:
Background: Vitamin D deficiency is one of the major public health concern due to its detrimental impact on bone health, particularly in rural settings with limited healthcare resources. Vitamin D is crucial for the absorption of calcium and metabolic function in bone, and its deficiency can lead to increased osteoclastic activity, lower bone mineral density (BMD), and higher fracture risks. This study investigates the effectiveness of various bone-forming agents in improving BMD among individuals with vitamin D deficiency in a rural tertiary care setting. Objective: To evaluate the impact of different bone-forming agents on BMD and vitamin D deficiency in a rural population and identify the most effective treatment modality. Methodology: A prospective observational study was conducted over six months at Dhiraj Hospital, Vadodara, Gujarat, India. A total of 102 participants with vitamin D deficiency, aged 18 or older, were enrolled and divided into three treatment groups: Zoledonate injection (Group 1), Ibandronate tablet (Group 2), and Calcitonin nasal spray (Group 3). BMD was assessed using bone densitometer scans at baseline and three months post-treatment. The T-score was categorized as Normal, Osteopenia, or Osteoporosis. Data were analyzed using Microsoft Excel. Results: Out of the 102 participants, 60(58.82%) were osteoporotic and 42(41.18%) were osteopenic at baseline. After treatment, osteoporosis decreased significantly from 60 to 15, while osteopenia increased from 42 to 85, with 2 showing normal BMD. Zoledonate and Ibandronate demonstrated the greatest improvement in BMD, with the largest effect sizes, while Calcitonin showed a modest improvement. Gender-specific and age-related differences in treatment outcomes were noted, with a substantial overall enhancement in BMD following treatment. Conclusion: Zoledonate and Ibandronate were more effective than Calcitonin nasal spray in improving BMD among patients with vitamin D deficiency. This study underscores the importance of targeted treatment strategies for bone health in rural populations. Future research should further explore these interventions' long-term benefits and applicability in similar settings.
Cite this article:
Rajesh A. Maheshwari, Aditya Agrawal, Meet Patel, Mansi Maheshwari, Vipul Patil, Rajesh Hadia, Hemraj Singh Rajput. Evaluating Bone Forming agents on Bone Mineral Density in Vitamin D Deficiency: A Prospective Observational Study in a Rural Tertiary Care Setting. Research Journal Pharmacy and Technology. 2025;18(12):5723-8. doi: 10.52711/0974-360X.2025.00826
Cite(Electronic):
Rajesh A. Maheshwari, Aditya Agrawal, Meet Patel, Mansi Maheshwari, Vipul Patil, Rajesh Hadia, Hemraj Singh Rajput. Evaluating Bone Forming agents on Bone Mineral Density in Vitamin D Deficiency: A Prospective Observational Study in a Rural Tertiary Care Setting. Research Journal Pharmacy and Technology. 2025;18(12):5723-8. doi: 10.52711/0974-360X.2025.00826 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-12-16
REFERENCES:
1. Holick MF. Vitamin D deficiency. The New England Journal of Medicine. 2007; 357(3): 266-81. doi: 10.1056/NEJMra070553.
2. Indumathi KP, Sibyl S. Vitamin D and its influence on oral health: A literature review. Research Journal of Pharmacy and Technology. 2023; 16(5): 2507-12. doi:10.3390/nu12051471.
3. Harini K, Priya VV, Gayathri R. Awareness of Importance of Vitamin D Among Dental Students in a Dental School-A Survey. Research Journal of Pharmacy and Technology. 2016; 9(8): 1133-6. doi: 10.5958/0974-360X.2016.00215.8.
4. Subashree R, Arjunkumar R. Vitamin D deficiency in periodontal health. Research Journal of Pharmacy and Technology. 2014; 7(2): 248-52. doi:10.5958/0974-360X
5. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocrine Reviews. 2001; 22(4): 477-501. doi:10.1210/edrv.22.4.0437.
6. Amanzholkyzy A, Nurgaliyeva RE, Kaldybayeva AT, Batyrova TZ, Balmaganbetova FK, Aibassova ZA. Biochemical variability of vitamin D receptor (Vdr) gene and its relationship with bone mineral density in children of the western region of the republic of Kazakhstan. Research Journal of Pharmacy and Technology. 2019; 12(2): 735-40. doi:10.5958/0974-360X.2019.00130.6.
7. Suha AF, Ali WM, Mohammed KI, Ali SH, Mousa JM, Hussein IQ. Correlation between Toxoplasmosis and Vitamin D Deficiency in women. Research Journal of Pharmacy and Technology. 2022; 15(9): 4073-7.
8. Shwetha MN, Priya P. Knowledge regarding vitamin D deficiency among students. Asian Journal of Nursing Education and Research. 2019; 9(1): 66-8. doi:10.5958/2349-2996.2019.00013.2.
9. Hill TR, Aspray TJ. The role of vitamin D in maintaining bone health in older people. Therapeutic Advances in Musculoskeletal Disease. 2017; 9(4): 89-95. doi:10.1177/1759720X17692502.
10. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. The Lancet. 1996; 348(9041): 1535-41. doi:10.1016/S0140-6736(96)07088-2.
11. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of Bone and Mineral Research. 2004; 19(8): 1241-9. doi:10.1359/JBMR.040325.
12. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. The New England Journal of Medicine. 2007; 356(18): 1809-22. doi: 10.1056/NEJMoa067312.
13. Suman VB, Chattterjee PK, Vinodini NA, Kunal K, Gokul M, Bhat RM. Effect of variable diet and physical activity on bone mineral density in adults using peripheral-Dexa scan. Research Journal of Pharmacy and Technology. 2018; 11(6): 2404-7. doi:10.5958/0974-360X.2018.00444.4.
14. Amrein K, Scherkl M, Hoffmann M, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. European Journal of Clinical Nutrition. 2020; 74(11): 1498-513. doi:10.1038/s41430-020-0558-y.
15. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. Journal of the American Medical Association. 2004; 291(16): 1999-2006. doi:10.1001/jama.291.16.1999.
16. Mugada VK, Kolkota RK, Srinivas SK, Rasheed A. Effectiveness of oral nano-particle based Vitamin D solution in pain management: a prospective cross-sectional study. Research Journal of Pharmacy and Technology. 2021; 14(1): 6-10. doi: 0.5958/0974-360X.2021.00002.0.
17. Lambrinoudaki I, Vlachou S, Galapi F, et al. Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women. Clinical interventions in aging. 2008; 3(3): 445-51. doi:10.2147/cia.s2046.
18. Vujasinović-Stupar N, Milić N, Petrović-Rackov L, et al. Efficacy and safety of once monthly ibandronate treatment in patients with reduced bone mineral density: Esther study. Srpski arhiv za celokupno Lekarstvo. 2010; 138(1-2): 56-61. doi:10.2298/sarh1002056v.
19. Orwoll ES, Binkley NC, Lewiecki EM, et al. Efficacy and safety of monthly ibandronate in men with low bone density. Bone. 2010; 46(4): 970-6. doi:10.1016/j.bone.2009.12.034.
20. Woo T, Adachi JD. Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis. Best Practice AND Research Clinical Rheumatology. 2001; 15(3): 469-81. doi:10.1053/berh.2001.0161.